NIST Human Factors in DNA Survey_TEST MODE_FINAL

Start of Block: Introduction

OMB Statement
OMB Control #0693-0043
Expiration Date: 03/31/2022

NIST Generic Clearance for Usability Data Collections

A Federal agency may not conduct or sponsor, and a person is not required to respond to, nor shall a person be subject to a penalty for failure to comply with an information collection subject to the requirements of the Paperwork Reduction Act of 1995 unless the information collection has a currently valid OMB Control Number. The approved OMB Control Number for this information collection is 0693-0043. Without this approval, we could not conduct this survey/information collection. Public reporting for this information collection is estimated to be approximately 45 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the information collection. All responses to this information collection are voluntary. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to the National Institute of Standards and Technology (NIST) point of contact: Melissa Taylor, melissa.taylor@nist.gov.

						 	-																					
P	201	a R	res	ak	_																							

Page Break

Thank you for taking part in this survey. The survey comprises questions relating to laboratory management, DNA interpretation, cognitive bias, training and research, testimony and reporting practices, and stakeholder engagement opportunities. Data from this survey will provide insight to inform best practice recommendations for forensic DNA interpretation.

This survey should be completed by the **DNA laboratory's TECHNICAL LEADER or equivalent.** This is the individual who is responsible for the technical oversight of the DNA laboratory, which may include (but is not limited to) day-to-day quality assurance and accreditation compliance, design and implementation of methods development, verification of analytical instrumentation function, and validation of new technologies.

Page Break			

This survey is best taken on a computer rather than mobile device.

Your responses will be saved as you work through the survey. If you stop and wish to complete at a different time, you will need to use the same device in order to resume at the last saved point. Please complete the survey within two weeks of starting it or your response will be recorded as incomplete.

End of Block: Introduction	
Start of Block: Laboratory Information	
Page Break —————	

Q2.1 This survey should be completed by the laboratory's technical leader or equivalent. Are you a technical leader or equivalent?
○ Yes
○ No
O Not sure
Display This Question:
If This survey should be completed by the laboratory's technical leader or equivalent. Are you a tec != Yes
Q2.2 If you answered "no" or "not sure" to the previous question, please end the survey here and forward the invitation link to the technical leader or equivalent, within your laboratory.
End survey now
I am a technical leader or equivalent
Skip To: End of Survey If If you answered "no" or "not sure" to the previous question, please end the survey here and forwa = End survey now
Q2.3 What type of crime laboratory or forensic science service provider (FSSP) do you represent?
O Publicly-funded local crime laboratory (to include city or town)
Publicly-funded county crime laboratory
O Publicly-funded state crime laboratory
Publicly-funded federal crime laboratory
O Private laboratory
○ Consultant

Q2.4 What region is your organization located in?
O New England (CT, ME, MA, NH, RI, VT)
○ Mid-Atlantic (NJ, NY, PA)
○ West North Central (IA, KS, MN, MO, NE, ND, SD)
Cast North Central (IL, IN, MI, OH, WI)
O South Atlantic (DE, FL, GA, MD, NC, SC, VA, DC, WV)
East South Central (AL, KY, MS, TN)
○ West South Central (AR, LA, OK, TX)
O Mountain (AZ, CO, ID, MT, NV, NM, UT, WY)
O Pacific (AK, CA, HI, OR, WA)
O Non-U.S. (please specify Country)
Display This Question: If What region is your organization located in? = Non-U.S. (please specify Country)
Q2.5 What continent is your laboratory in?
O Asia
O Europe
O South America
Oceania (Australia, New Zealand)

Q2.6 Who is	22.6 Who is (are) your primary customer(s)? (Select all that apply)						
	Law enforcement (local, county, state, federal)						
	Prosecutor						
	Defense attorney						
	Private client						
	Other (please specify)						

Q2.7 What Fo	prensic DNA services are you providing to your primary customer(s)? (Select all
	Autosomal STR
	Mitochondrial
	Y-STR
	Next Generation Sequencing
	Mixture Interpretation
	Probabilistic Genotyping
	CODIS upload and search
	Familial Searching
	Forensic Genealogy
	Paternity/parentage (criminal)
	Paternity/parentage (non-criminal)
	Phenotyping
	Other (please specify)
Page Break	

Q2.8 Does your laboratory track the TYPE of DNA samples that you routinely analyze? (e.g., track whether a sample is liquid blood, saliva stains, dried semen stains, touch DNA, etc.)
○ Yes
○ No
O Not sure
O Not applicable
Display This Question:
If Does your laboratory track the TYPE of DNA samples that you routinely analyze? (e.g., track wheth = Yes
Or Does your laboratory track the TYPE of DNA samples that you routinely analyze? (e.g., track wheth = Not sure
Q2.9 What are the categories that your laboratory uses to track DNA samples? (Select all that apply)
O Bodily fluid type
○ Case scenario
○ Crime type
O Number of contributors
Template amount
O Evidence item type (e.g., gun, clothing)
Other (please list)
O Not applicable
Page Break

Q2.10 How many DNA analysts does your FSSP employ?

For the purpose of this survey, a DNA <u>analyst</u> is defined as: an employee or contract employee, that successfully completed the laboratory's training requirements for casework sample analysis, passed a competency test, and has entered into a proficiency testing program according to these standards. This individual can conduct and/or direct the analysis of forensic samples, interpret data, reach conclusions, and generate reports.

This definition includes both persons who process the DNA samples and those who perform the statistical analysis and interpretation of the DNA results (for laboratories who separate these unctions).
\bigcirc 0
O 1-5
O 6-10
O 11-30
O 31-50
O >50
Q2.11 In your laboratory, do the same analysts perform both the analytical/instrument processing and the interpretation of DNA results, or are these functions separated? Analysts perform all aspects of the analysis and interpretation These functions are separated Combination of both Other (please specify)

Q2.12 Does your laboratory or agency employ a human subjects officer (or similar)?

A human subjects officer (or similar) is a generally a person responsible for reviewing and

approving (or seeking appropriate approvals for) human-subjects research in the laboratory/agency. They will likely coordinate and manage institutional review board (IRB) activities and other compliance activities.)
○ Yes	
○ No	
O Don't know	

End of Block: Laboratory Information

Start of Block: Tasks that the lab performs

Q3.1 How often does your laboratory perform the following tasks?

Note: Direct-to-DNA is a DNA casework approach in which serology is removed from the workflow as the initial screening of a Sexual Assault Kit sample, and instead, the initial

screening is completed during the DNA quantification step to determine the level of male DNA among female DNA to inform downstream processing.

	Rarely	Sometimes	Often	Always	Not applicable
Presumptive test for semen	0	0	0	0	0
Presumptive test for blood	\circ	\circ	\circ	\circ	\circ
Presumptive test for saliva	\circ	\circ	\bigcirc	\circ	\circ
Microscopic search for sperm	\circ	\circ	\circ	\circ	\circ
Confirmatory test for blood	\circ	\circ	\circ	\circ	\circ
Confirmatory test for saliva	\circ	\circ	\circ	\circ	\circ
Y-STR typing	0	\circ	\circ	\circ	\circ
Direct-to- DNA approach	0	0	\circ	\circ	0

Display This Question:

If How often does your laboratory perform the following tasks? Note: Direct-to-DNA is a DNA casewo... != Y-STR typing [Rarely]

Q3.2 At what	point in the workflow is Y-STR typing incorporated (Select all that apply)					
	At the biological screening stage					
	After quantitation					
	After initial autosomal STR results are obtained and evaluated.					
	When specifically requested by the client.					
	When specifically requested for court purposes.					
	Other (please specify)					
Display This Question:						
	n does your laboratory perform the following tasks? Note: Direct-to-DNA is a DNA STR typing [Rarely]					
	Q3.3 Which criteria are used to inform the incorporation of Y-STR typing? (Select all that apply)					
	Based on screening results.					
	Based on male DNA/ratio results.					
	Based on autosomal STR results.					
	If specifically requested by the client.					
	If specifically requested for court purposes.					
	Other (please specify)					
End of Block: Tasks that the lab performs						

Start of Block: Communication of results and testimony

Page Break —

The followin	The following questions relate to reporting and testimony.					
Q4.1 How are	e your laboratory's reports formatted?					
	rive (written explanations or paragraphs that describe evidence/items tested and results and opinions)					
O Tabula	ar (lists and tables of the evidence/items tested and the DNA results and opinions)					
O Comb	ination					
O Not su	ıre					
Q4.2 How and	d why did you select that format? (Select all that apply)					
	Clarity					
	Brevity					
	Aesthetic					
	Simplicity					
	It has always been formatted that way					
	Not sure					
	Other (please specify)					

	How/why ct all that	apply)			
		Based on published research pertaining to effective communication			
IS	SO, NAS.	Based on best-practice recommendations from guidance bodies (e.g., ISFG, etc.)			
		Based on feedback from stakeholders (e.g., lawyers, investigators)			
		Based on internal research (e.g., in consultation with DNA analysts)			
		The language we use now is the language we've always used			
		Not sure			
		Other (please specify)			
	Q4.4 Is your DNA laboratory reporting a quantitative value only or a combination of quantitative and qualitative statements?				
	O Quantitative only (Likelihood Ratio or other numerical value)				
	O Qualitative only (verbal equivalent or written explanation)				
	Quanti	tative and qualitative			
	Not sur	re			

Q4.5 Does your laboratory have a standard operating procedure for testimony (to include recommendations on how to testify to specific results)?
○ Yes
○ No
O Not sure
O Not applicable
Q4.6 Does your laboratory have a procedure to monitor testimony?
○ Yes
○ No
O Not sure
O Not applicable

Q4.7 How often do analysts within your laboratory:

	Never	Sometimes	About half the time	Most of the time	Always	Not applicable
Solicit (and receive) feedback from your customers specific to the comprehension of your reports?	0	0	0	0	0	0
Attend a pre- trial conference with the prosecution?	0	0	0	0	0	0
Attend a pre- trial conference with the defense?	0	0	0	0	0	0
Offer forensic reports as evidence exhibits in court? (rather than simply referring to them during testimony)	0	0		0	0	0
Use visual aids during testimony?	0	0	0	0	0	0

Start of Block: Contextual information management / bias management / QA / QC

Q5.1 Which of the following terms does your laboratory regularly use as part of your quality management system? (Select all that apply)				
Analyst Error				
Conflict				
Deviation from protocol				
Disagreement				
Error				
Incident				
Instrument Error				
Lapse				
Mistake				
Non-conformity				
Quality Issue				
Slip				
Systematic Error				
Technological Error				
Unexpected finding				
Other (please specify)				

25.2 How does your laboratory define "error", "disagreement", "conflict", or any other erms that it regularly uses? Please include the term(s) and definition(s) here or write	
Page Break ————————————————————————————————————	

nsus is not reached following a technical review, which of the following steps could (Select all that apply)
Conversation between reviewer and analyst
Mediation by supervisor
Mediation by technical leader
Involve the quality manager
Re-amplification of sample by original analyst
Re-amplification of sample by second analyst
Independent re-interpretation by third party
Send to independent laboratory for complete re-analysis
Report the most conservative opinion
Report an inconclusive opinion
Report both opinions
Not reporting the case
No action
Other (please specify)

Q5.4 If any results or opinions are changed as a result of the review processes, how are the disagreement/non-consensus and action documented? (Select all that apply)				
	Report			
	Case file			
	Personnel file			
	Not documented			
	Other (please specify)			
	Review process would not change results or opinions			

•	(Select all that apply)
	Quality Manager
	Technical Leader
	Prosecution
	Defense
	Client (if not prosecution or defense)
	Law Enforcement
	Other (please specify)
	No one (it is not disclosed)
	Review process would not change results or opinions

Q5.6 If a char	nge of result or opinion is disclosed, how is it disclosed? (Select all that apply)
	Not disclosed
	Phone call to client
	Email to client
	Within report
	Within routinely disclosed case file
	Within case file disclosed upon request
	Upon request
	Oral testimony
	Pre-trial case conference with prosecution
	Pre-trial case conference with defense
	Other (please specify)
Page Break	

Q5.7 What typ (QMS)?	be of risk assessment do you perform as part of your Quality Management System
risk event	Matrix-based (based on intersecting factors; for example, the likelihood that the will occur, and the potential impact that the risk event could have)
level, toler	Level-based (based on categories of risk tolerance, for example: acceptable rable level, and intolerable level)
	Other (please specify)
	Not applicable ■ Not applicable Not applicable
Display This Q	uestion:
	be of risk assessment do you perform as part of your Quality Management System (QMS)?
Q5.8 What fac	ctors do you consider in your risk assessment? (Select all that apply)
	Frequency
	Effect on reported opinion
	Likelihood of occurrence
	Likelihood of detection
	Cost
	Severity
	Other (please specify)
Page Break	

Q5.9 How do you monitor DNA analysts' abilities to perform complex tasks (excluding routine open proficiency testing), and how often?

	Monthl y	Quarterl y	Biannuall y	Yearl y	Bienniall y	When require d	Neve r	Not sur e
In-house testing/researc h	0	0	0	0	0	0	0	C
Internal collaborative exercises	0	\circ	0	\circ	\circ	0	\circ	C
Inter-laboratory exchange	0	\circ	\circ	\circ	\circ	0	0	(
Training exercises	0	\circ	\circ	\circ	\circ	\circ	\circ	(
Blind proficiency tests	0	\circ	\circ	0	\circ	\circ	\circ	C
Other (please specify or select "never")	0	0	\circ	0	0	0	0	(
exchange Training exercises Blind proficiency tests Other (please specify or	0	0	0	0	0	0		

Page 26 of 70

Q5.10 Does your laboratory use any sort of blinding during casework?

	Yes, formalized in SOPs	Yes, but not formalized in SOPs	No	Not sure
Sequential unmasking (task- relevant information presented in sequential order, for example evidence/item sample analyzed before reference sample)	0	0	0	0
Context manager (someone who filters task- relevant and task-irrelevant information and only passes on to the analyst that which is deemed to be task-relevant)				
Blind technical review (reviewer does not know original analyst's interpretation opinion)	0	0	0	0
Blind reanalysis of samples (re- analyze samples without knowing original result)	0	0	0	0
Blind review of Number-of- Contributors assessments (assess NoC without knowing original analyst's opinion)	0	0	0	0

Blind data review (review data without knowing original analyst's opinion)	0	0	0	0
Blind interpretation of Probabilistic Genotyping Software outputs (interpretation of PGS outputs without knowing original analyst's interpretation)	0	0	0	0
Blind genotyping/EPG assessment (assessment of genotyping/EPG without knowing original analyst's assessment)			0	0
Page Break ——				

Q5.11 Please indicate your level of agreement with the following statements.

Note: Depending on the device that you are viewing this on, you may need to scroll across or down to see all options.

	Strongly disagree	Somewhat disagree	Neither agree nor disagree	Somewhat agree	Strongly agree
The interpretation of DNA data can be influenced by the information given to the DNA analyst.	0	0	0	0	0
Bias can still occur when using Probabilistic Genotyping Software.	0	0	0	0	0
The research community should conduct more studies about contextual bias in forensic biology before our laboratory will change or implement contextual information management policies.				0	
We already know enough about cognitive bias in forensic biology to start making policy changes in our laboratory.					

Cognitive bias can affect forensic biologists' interpretation of DNA data.	0	0	0	0	0
All forensic analysts should be aware of cognitive bias.	0				0

Q5.12 Please indicate your level of agreement with the following statements.

	Strongly disagree	Somewhat disagree	Neither agree nor disagree	Somewhat agree	Strongly agree
Cognitive bias is a bigger issue for analysts in other forensic disciplines than those in forensic biology.	0	0	0	0	0
Knowing about the reference profile before examining a complex DNA mixture can affect how a DNA analyst interprets the mixture.					
Knowing about a confession before examining a complex DNA mixture can affect how a DNA analyst interprets the mixture.				0	0
Knowing one DNA analyst's Number-of-Contributor determination can affect another DNA analyst's Number-of-Contributor determination.				0	0

Likelihood ratios prevent contextual bias in forensic biology.	0	0	0	0	0
Probabilistic Genotyping Software prevents bias in forensic biology.	0	0	0	0	0
End of Block: Contextual information management / bias management / QA / QC Start of Block: Probabilistic Genotyping					

on Probabilistic	re interested in your laboratory's data interpretation methods, with an emphasis Genotyping Software (PGS). If your laboratory is not using PGS, please select where appropriate.
	ne following statistical analysis methods does your laboratory use for autosomal on? (Select all that apply)
С	ombined Probability of Inclusion / Random Man Not Excluded
Li	kelihood Ratio
R	andom Match Probability
	ther (please specify)
Q6.3 Has your la	aboratory implemented, or is it in the process of implementing, PGS?
O Not using	PGS and have no plans to
O Not using	PGS but may in the future
O In the pro	ocess of validating, but not using in casework
O Validated	I and online
O Validated	I, online, and in the process of validating an updated version
Display This Ques	tion:
	boratory implemented, or is it in the process of implementing, PGS? = Not using PGS
And Has your PGS but may in th	laboratory implemented, or is it in the process of implementing, PGS? = Not using the future

Q6.4 What to hat apply)	ol(s) is your laboratory using to calculate a statistic for DNA opinions? (Select all
	Spreadsheet
	Manual
	Not calculating a statistic
	Other (please specify)
Display This Q	uestion:
	r laboratory implemented, or is it in the process of implementing, PGS? = In the process of not using in casework
Or Has yo online	ur laboratory implemented, or is it in the process of implementing, PGS? = Validated and
Or Has yo	ur laboratory implemented, or is it in the process of implementing, PGS? = Validated,

Q6 app		GS is your laboratory using or in the process of implementing? (Select all that
		STRmix (include version number)
		TrueAllele (include version number)
		EuroForMix (include version number)
		MixCal6 (include version number)
		LiRa (include version number)
		Other (please specify developer and version number)
		uestion: r laboratory implemented, or is it in the process of implementing, PGS? = In the process of not using in casework
onli	Or Has yo	ur laboratory implemented, or is it in the process of implementing, PGS? = Validated and
	Or Has yo	ur laboratory implemented, or is it in the process of implementing, PGS? = Validated, he process of validating an updated version
Q6		r will) your laboratory train ALL DNA casework analysts to use and report PGS
	O Yes	
	○ No	
	O Not ap	pplicable

Display This Question:

If Does (or will) your laboratory train ALL DNA casework analysts to use and report PGS outputs? =

Q6.7 Approximately what percentage of fully trained DNA casework analysts are also trained to use and report PGS outputs?

0 10 20 30 40 50 60 70 80 90 100

Please move slider to indicate the percentage of DNA analysts in your laboratory who are trained on PGS.

Q6.	8 Does yo	ur laboratory routinely perform replicate amplifications?
		Yes
		No
		Case/sample dependent (please describe)
•		Not applicable
		ur laboratory have a minimum amplification threshold based on quantification ct all that apply)
		⊗ No minimum threshold
		Total amount of DNA
		M:F ratio
		Other (please specify)
	ao Proole	
F2(ie Break	

Q6.10 An idea being discussed in the DNA community is to create a central repository of validation summaries that multiple laboratories could contribute data to and use. This repository could be accessible to all stakeholders/interested parties (including attorneys and researchers), or it could be password-protected and only available to other DNA laboratories (i.e., private).

Please read the following statements and select the one that best applied	es to your laboratory:				
Our laboratory would use a central repository, regardless of who	can access it.				
Our laboratory would only use a central repository if it was priva-	te.				
O I do not know if our laboratory would use a central repository.					
Our laboratory would not use a central repository.					
O Validation summaries are not applicable to our laboratory.					
Q6.11 Please read the following statements and select the one that bes	t applies to your				
Our laboratory would contribute data to a central reposito can access it.	ory, regardless of who				
Our laboratory would contribute data to a central repositor private.	ory, but only if it was				
I do not know if our laboratory would contribute data to a	central repository.				
Our laboratory would not contribute data to a central repo	ository.				
Validation summaries are not applicable to our laboratory	/.				
Q6.12 Please comment on why your laboratory would or would not be able to contribute to or use such a repository.					

Q6.13 Some laboratories use internally-collected DNA samples for their validation studies (e.g., from staff members). Collecting samples in this way may restrict sharing data outside of the laboratory due to privacy concerns. Would your laboratory benefit from access to appropriately consented, externally-collected DNA samples to use in your validation studies? We already obtain external DNA samples We do not currently obtain external DNA samples but would benefit from such samples O No, we would not benefit O Not sure O Not applicable Q6.14 Has your laboratory encountered any barriers to creating complex DNA mixture samples for your internal validation exercises? Please discuss or type "not applicable". Page Break —

Q6.15 Does your laboratory print out electropherograms for the case file?
○ Yes
○ No
O Not sure
O Not applicable
Q6.16 Does your laboratory save electronic data for all PGS runs even if some runs are not used to render the final report conclusion (e.g., an alternate contributor number was evaluated and rejected)?
O Yes, save all runs
O No, do not save all runs
O Not sure
O Not applicable
Q6.17 Does your laboratory have a method in place (other than routine network back-ups) for tracking and maintaining the integrity of all saved electronic files related to PGS?
○ Yes
○ No
O Not sure
O Not applicable
End of Block: Probabilistic Genotyping
Start of Block: Internal Training Opportunities Page Break

The following questions relate to training.					
[X]					
Q7.1 To wha	t level are DNA analysts within your laboratory trained? (Select all that apply)				
	To minimum accreditation standards				
	To perform relevant laboratory techniques				
	To explain case file content to stakeholders (separate from court testimony)				
	To participate in an admissibility hearing				
	To testify in court				
	Other (please specify)				
Carry Forward	Selected Choices from "To what level are DNA analysts within your laboratory trained?				
(Select all that					
Q7.2 Please indica	ate all ways that performance is assessed for each task.				

Note: Depending on the device that you are viewing this on, you may need to scroll across or

down to see all options.

	Oral Exam	Written Exam	Moot Court	We do not assess performance on this task	Other		
To minimum accreditation standards							
To perform relevant laboratory techniques							
To explain case file content to stakeholders (separate from court testimony)							
To participate in an admissibility hearing							
To testify in court							
Other (please specify)							
Q7.3 Does your laboratory provide in-house training for DNA analysts? Yes No No, but our laboratory does provide external training opportunities							
O Not sure	, , . .		3 · Fr				



Q7.4

In choosing content for your laboratory's DNA analyst training program, did your laboratory follow recommendations from any of the following groups? (Select all that apply)

FBI Quality Assurance Standards (QAS)
International Organization for Standardization (ISO)
International Society for Forensic Genetics (ISFG)
Scientific Working Group on DNA Analysis Methods (SWGDAM)
The Organization of Scientific Area Committees for Forensic Science (OSAC)
Other (please specify)
Not sure
None of the above

Display This Question:

If In choosing content for your laboratory's DNA analyst training program, did your laboratory follo... != Not sure

And In choosing content for your laboratory's DNA analyst training program, did your laboratory follo... != None of the above

Carry Forward Selected Choices from "In choosing content for your laboratory's DNA analyst training program, did your laboratory follow recommendations from any of the following groups? (Select all that apply)"



Q7.5 How adequate are the documents provided by the groups you selected previously for guiding training?

	Extremely inadequat e	Somewha t inadequat e	Neither adequate nor inadequat e	Somewh at adequate	Extremel y adequat e	Not sur e	Not applicabl e
FBI Quality Assurance Standards (QAS)	0	0	0	0	0	(0
International Organization for Standardizati on (ISO)	0	0	0	0	0	(0
International Society for Forensic Genetics (ISFG)	0	0	0	0	0	(0
Scientific Working Group on DNA Analysis Methods (SWGDAM)	0	0	0	0	0	(0
The Organization of Scientific Area Committees for Forensic Science (OSAC)	0	0	0	0	0	(0
Other (please specify)	0	\circ	\circ	\circ	0	(\circ
⊗Not sure	0	\circ	\circ	\circ	\circ	(\circ
None of the above	0	\circ	\circ	\circ	0	(\circ

	se elaborate on your views of the adequacies (or not) of the training docum atory used to guide training.	ents that
Page Brea		

Q7.7 How long does it usually take a DNA analyst to complete their training at your agency?
O 0-3 months
O 4-6 months
O 7-9 months
O 10-12 months
○ >12 months
O Not sure
Q7.8 Would you like to see more national training efforts similar to programs offered by the National Forensic Science Technology Center (NFSTC)?
○ Yes
○ No
O Not sure
O Do not know what the NFSTC offers
×

Q7.9 Who pro all that apply)	Q7.9 Who provides training and continuing education to DNA analysts at your agency? (Select all that apply)											
	Designated training coordinator	(inte	rnal t	o ag	ency	·)						
	Training team (internal to agend	;y)										
	Occasional trainers (e.g., extern	nal sp	eake	ers oi	r ven	dors))					
	Other (please specify)											
	Not sure											
	Not applicable											
	uestion: vides training and continuing educat ed training coordinator (internal to ag			anai	lysts a	at yol	ur ag	ency	? (Se	elect	all th	at
Q7.10 What pactivities?	percent of your <u>designated traini</u>	ng c	<u>oord</u>	inate	<u>or's</u> t	ime i	is de	edica	ited t	o tra	iinin	g
activities?				Nor	ne					All		
		0	10	20	30	40	50	60	70	80	90	100
% (of time spent on training activities						I					
	uestion: vides training and continuing educat team (internal to agency)	tion to	DNA	anaı	lysts a	at yoı	ur ag	ency	:? (Se	elect a	all th	at

Q7.11

Excluding any designated training coordinator, approximately how many <u>Full Time Equivalent</u> <u>positions</u> in your <u>training team</u> are dedicated to supporting training and education?

For the purpose of this survey, a Full Time Equivalent (FTE) position is defined as equal to

ac	tivities.	
	○ < 0.5	
	O 0.5	
	\bigcirc 1	
	O 1.5	
	O 2	
	O 2.5	
	○ 3	
	O 3.5	
	O 4	
	O 4.5	
	O 5 +	

If Who provides training and continuing education to DNA analysts at your agency? (Select all that

Display This Question:

a... = Occasional trainers (e.g., external speakers or vendors)

a 40 hour full-time working week. So, if you have two team members working as a training team to provide training and education, and each team member spends half of their time on training and education activities, you have 1 FTE team member dedicated to training and education

Q7.12

On average, how many times *per year* does an <u>occasional trainer</u> come to your agency to provide training to DNA analysts?

3-5 times

6-10 times

>10 times

O Not sure

Not applicable

Display This Question:

If Who provides training and continuing education to DNA analysts at your agency? (Select all that a... != Not sure

And Who provides training and continuing education to DNA analysts at your agency? (Select all that a... != Not applicable

Carry Forward Selected Choices from "Who provides training and continuing education to DNA analysts at your agency? (Select all that apply)"



Q7.13 How were those who provide training and continuing education for DNA analysts in your agency selected for their role? (Select all that apply for each factor contributing to trainer selection)

Sciediony	Opt in/ volunte er	Word of mouth/ recommenda tion	Relevant professio nal/ technical experienc e	Relevan t training experien ce	Capacit y/ availabil ity	Best fitting role for the perso n within the agen cy	No t sur e	Not applica ble
Designat ed training coordina tor (internal to agency)							(
Training team (internal to agency)								
Occasio nal trainers (e.g., external speaker s or vendors)							(
Other (please specify)							(
Not sure								
Not applicable								

Display This Question:

If Who provides training and continuing education to DNA analysts at your agency? (Select all that a...!= Not sure

And Who provides training and continuing education to DNA analysts at your agency? (Select all that a... != Not applicable

Carry Forward Selected Choices from "Who provides training and continuing education to DNA analysts at your agency? (Select all that apply)"



Q7.14 Have those who provide training and continuing education for DNA analysts in your agency completed any training on **how to train others**?

	Yes	No	Not sure	Not applicable
Designated training coordinator (internal to agency)	0	0	0	0
Training team (internal to agency)	0	0	0	0
Occasional trainers (e.g., external speakers or vendors)	\circ	0	0	
Other (please specify)	\circ	0	0	\circ
⊗ Not sure	0	\circ	\circ	\circ
Not applicable	\circ	0	0	\circ

End of Block: Internal Training Opportunities	
Start of Block: External Training Opportunities	
Page Break ————————————————————————————————————	_

Q8.1 Does your agency provide a budget to offer DNA analysts training from outside your organization (e.g., to attend conferences, workshops, meetings, etc.)?
○ Yes
○ No
O Not sure
Display This Question:
If Does your agency provide a budget to offer DNA analysts training from outside your organization (!= Not sure
Q8.2 How adequate is the budgeted amount (even if \$0)?
Extremely adequate
Somewhat adequate
Somewhat inadequate
Extremely inadequate
O Not sure
Page Break ————————————————————————————————————

Q8.3 Does yo your organiza	ur agency rely on external grants to provide DNA analysts training from outside tion?
O Yes	
○ No	
O Not su	re
Display This Q	uestion:
If Does you organ = Yes	ur agency rely on external grants to provide DNA analysts training from outside your
Q8.4 Please s that apply)	specify the source(s) of the external grants that your agency relies on. (Select all
	State Coverdell Funds
	National Institute of Justice (NIJ) / Bureau of Justice Assistance (BJA)
	National Institute of Standards and Technology (NIST)
	Capacity Enhancement for Backlog Reduction (CEBR) grants
	Other (please specify)
Page Break	

Q8.5 What percenta	-	s in your lab	orato	ry att	end	train	ing e	exter	nal t	o yo	ur	
·		0	10	20	30	40	50	60	70	80	90	100
% of DNA ar	nalysts who attend of training ea			-			ı	_				
X												
Q8.6 How is information	ation from external Always	training opp Ofter		ties		ed wi netin		thers	in y	our a Nev	-	ıcy?
Report to supervisor	0	C)			C)				0	
Presentation to colleagues	\circ)			C)				\circ	
Written summary	\circ	C)			C)			(\circ	
Other (please specify)	\circ	C)			C)				\bigcirc	
Page Break ———												

Q8.7 Do DNA analysts at your agency have access to peer-reviewed publications (e.g., journals, conference proceedings)?
O Yes
○ No
O Not sure
Q8.8 How adequate is the budget to provide DNA analysts with access to peer-reviewed publications (even if \$0)?
Extremely adequate
Somewhat adequate
O Somewhat inadequate
Extremely inadequate
O Not sure
Q8.9 Does your agency run a "journal club" or similar for DNA analysts?
Note: a journal club is typically an informal meeting to discuss peer-reviewed journal articles, book chapters, or conference proceedings.
○ Yes
○ No
O Not sure

	ere any incentives or requirements for DNA analysts in your agency to read peer- ications? (Select all that apply)
	Yes - Accreditation
	Yes - Promotion
	Yes - Remuneration
	No
	Other (please specify)
	Not sure
	Not applicable
* [%]	

•	agency had unlimited resources to enhance the training and continuing education sts in your laboratory, what would be your TOP TWO priorities?
	Funding for external conferences
	Access to peer-reviewed publications
	A dedicated training coordinator
	An expanded training team
	Funding for occasional training (e.g., from vendors)
	Better training and education materials
	My agency already has all the training and education resources needed
	Other (please specify)
End of Block	: External Training Opportunities
Start of Block	k: Stakeholder engagement
Page Break	

Q9.2 Which stakeholder groups does your laboratory engage with throughout the process of a DNA examination? (Select all groups and stages that apply)								
	Submission of evidence	Processing of evidence	Reporting results	Pre- trial	Trial	Post- trial	Never	
Law enforcement								
Prosecution								
Defense								
Judge								
Defendant								
Complainant								
Other FSSPs								

Q9.3 How important is communication between your laboratory and the stakeholders:

	Extremely important	Very important	Moderately important	Slightly important	Not at all important	Not applicable
When evidence/items are received by the laboratory for DNA processing?	0	0	0	0	0	0
During the processing of evidence/items?	0	0	0	0	0	0
When reporting results?	\circ	\circ	\circ	\circ	\circ	\circ
In preparing for trial (i.e., pre-trial)?	0	\circ	0	0	\circ	0
During the trial?	\circ	\circ	\circ	\circ	\circ	\circ
At the conclusion of a trial? (i.e., post-trial)	0	0	0	0	0	0
Page Break ——						



following types of information when evidence/items are received by the laboratory for DNA processing? Please rank in order of importance with 1 being the most important.
Note: click and drag each option to move into order of importance. Information about probative items Information about the number of items Information about case prioritization (rush, trial status, etc.) Information about the case scenario Information about the crime scene
×
Q9.5 How important is communication between your laboratory and stakeholders about the following types of information during the processing of DNA evidence? Please rank in order of importance with 1 being the most important.
Note: click and drag each option to move into order of importance.
Information about DNA standards Information about CODIS eligibility Information about additional items and/or rounds of DNA testing
×
Q9.6 How important is communication between your laboratory and stakeholders about the following types of information after the processing of DNA evidence? Please rank in order of importance with 1 being the most important.
Note: click and drag each option to move into order of importance.
Information about CODIS confirmation standards
Information about case discovery Information about pre-trial hearings

_____ Information about pre-trial interviews

_____ Information about the trial

Page Break			_

Q9.7 How satisfied are you with the communication between your laboratory and the stakeholders at each phase of the case?

	Extremely satisfied	Slightly satisfied	Neither satisfied nor dissatisfied	Slightly dissatisfied	Extremely dissatisfied	Not applicable
When evidence/items are received by the laboratory for DNA processing	0	0	0	0	0	0
During the processing of evidence	0	\circ	0	0	0	0
When reporting of results	0	\circ	0	\circ	\circ	\circ
In preparing for trial (i.e., pre-trial)	0	\circ	\circ	\circ	\circ	\circ
During the trial	0	\circ	\circ	0	0	0
At the conclusion of a trial (i.e., post-trial)	0	0	0	0	0	0

	echanisms are in place for stakeholders to access information from your Select all that apply)					
	Phone					
	Email					
	Website					
	Laboratory director					
	DNA technical leader					
	Case manager					
	Report					
	Site visit					
	Other (please specify)					
-	portant is it for your laboratory to communicate with stakeholders regarding quality as contamination, sample loss, analyst error, changed procedure, misconduct, or					
O Extren	nely important					
	O Very important					
	ately important					
	y important					
	all important					
	พูมเบลมเ บ					

[X]	
	ortant is it for your laboratory to communicate with stakeholders regarding the incidents? Please rank in order of importance with 1 being the most important.
Note: click and compared to the contamination of th	loss error d procedure luct
	ources would improve communication between your laboratory and the elect all that apply)
G	lossary
Т	raining
To pathways/int	echnology solutions, software packages, RMS communication erfaces
O w	/eb resources/how-to guides
☐ In	oformational bulletins
	Other (please specify)
Page Break —	

End of Block: Stakeholder engagement	
Start of Block: Feedback	
Q10.1 If you wish to provide any feedback or additional comments about this survey, the box below or email nikola.osborne@nist.gov	please use
Click next to complete the survey.	
End of Block: Feedback	